Why target 2035

Almost 20 years after the human genome was sequenced, many of the genes linked to disease phenotypes or those associated with specific disease traits by genome-wide association studies remain severely understudied: the so-called ‘dark genome’.

Generating chemical and biological reagents for these understudied proteins will enable research, lead to the validation of novel therapeutic targets, and the discovery of better medicines.